Immunotherapy combinations for colorectal cancer with liver tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have colorectal cancer that has spread to your liver.
- You are planning to have surgery to remove the liver tumors.
- Your tumor is not a type called MSI-H or dMMR.
- You have not had certain immunotherapies (like Keytruda, Opdivo, or Yervoy) before.
- You are willing to let researchers study your tumor tissue after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests a new way to deliver immunotherapy directly into the liver for people with colorectal cancer that has spread only to the liver. The goal is to see if this approach can shrink tumors before surgery, and it may be an option if you've already had standard chemotherapy.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
This trial combines targeted radiation (SBRT) with an immunotherapy drug (PD-1 inhibitor) to treat colorectal cancer that has spread to the liver and can't be removed by surgery. It aims to help shrink or control tumors in patients whose cancer has a normal DNA repair system (pMMR/MSS).
This trial tests a combination of two targeted drugs (sintilimab and bevacizumab) with chemotherapy for people whose colorectal cancer has not spread to the liver. It aims to see if this combo helps control the cancer better after the first treatment stops working.
Hear when a new Liver Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.